Retatrutide: What It Is, How It Works, and What Research Shows

Retatrutide has become one of the most discussed compounds in metabolic research over the past two years. It belongs to the GLP-1 class of peptides but goes further than its predecessors, targeting three receptors instead of one or two. Here's what that means and what the research shows.

What Is Retatrutide?

Retatrutide is a synthetic peptide that acts as a triple agonist, meaning it activates three different hormone receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple mechanism is what distinguishes it from semaglutide, which targets only GLP-1, and tirzepatide, which targets GLP-1 and GIP.

The compound was developed by Eli Lilly and has been in clinical trials studying its effects on weight, metabolic function, and related conditions.

How Does Retatrutide Work?

Each of the three receptors retatrutide activates plays a different role. GLP-1 receptor activation slows digestion and reduces appetite. GIP receptor activation works alongside GLP-1 to enhance insulin response and may play a role in fat metabolism. Glucagon receptor activation increases energy expenditure, meaning the body burns more calories at rest. The combination of these three mechanisms is what researchers believe produces the significant metabolic effects seen in early trials.

Retatrutide vs. Semaglutide vs. Tirzepatide

Semaglutide (the active compound in Ozempic and Wegovy) targets one receptor: GLP-1. Tirzepatide (the active compound in Mounjaro) targets two: GLP-1 and GIP. Retatrutide targets all three. In the Phase 2 clinical trial published in the New England Journal of Medicine in 2023, participants taking the highest dose of retatrutide lost an average of 24% of their body weight over 48 weeks, a figure that exceeded results seen in comparable trials for semaglutide and tirzepatide.

What Does the Research Show?

The 2023 Phase 2 trial was the landmark study. It enrolled 338 adults with obesity and showed dose-dependent weight reduction across all groups, with the highest dose group achieving the 24% average figure. Retatrutide also showed improvements in blood sugar, blood pressure, and lipid levels. Phase 3 trials are ongoing as of 2026.

Retatrutide Side Effects: What Research Has Documented

The most commonly reported side effects in trials were gastrointestinal: nausea, vomiting, diarrhea, and constipation, similar to those seen with semaglutide and tirzepatide. These were generally dose-dependent, meaning higher doses produced more frequent side effects. Most were reported as mild to moderate. The trial also noted a small increase in heart rate, which is being monitored in ongoing Phase 3 studies.

Where Researchers Source Retatrutide

For research purposes, verified suppliers like Werner Science carry research-grade retatrutide. Browse their catalog at wernerscience.com/?ref=bwmucbwp